Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

LUNG

Pulmonx (LUNG)

Pulmonx Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LUNG
DateHeureSourceTitreSymboleSociété
27/11/202400h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LUNGPulmonx Corporation
22/11/202422h28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LUNGPulmonx Corporation
20/11/202422h05GlobeNewswire Inc.Pulmonx to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:LUNGPulmonx Corporation
19/11/202415h00Business WirePulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and ProvidersNASDAQ:LUNGPulmonx Corporation
15/11/202401h47Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LUNGPulmonx Corporation
07/11/202422h05GlobeNewswire Inc.Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNASDAQ:LUNGPulmonx Corporation
05/11/202422h05GlobeNewswire Inc.Pulmonx to Present at the Stifel 2024 Healthcare ConferenceNASDAQ:LUNGPulmonx Corporation
01/11/202421h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LUNGPulmonx Corporation
30/10/202421h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LUNGPulmonx Corporation
30/10/202421h05GlobeNewswire Inc.Pulmonx Reports Third Quarter 2024 Financial ResultsNASDAQ:LUNGPulmonx Corporation
16/10/202422h05GlobeNewswire Inc.Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024NASDAQ:LUNGPulmonx Corporation
09/09/202422h05GlobeNewswire Inc.Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024NASDAQ:LUNGPulmonx Corporation
29/08/202422h05GlobeNewswire Inc.Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth ConferenceNASDAQ:LUNGPulmonx Corporation
22/08/202422h05GlobeNewswire Inc.Pulmonx to Present at the 2024 Wells Fargo Healthcare ConferenceNASDAQ:LUNGPulmonx Corporation
31/07/202422h05GlobeNewswire Inc.Pulmonx Reports Second Quarter 2024 Financial ResultsNASDAQ:LUNGPulmonx Corporation
29/07/202422h05GlobeNewswire Inc.Pulmonx to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:LUNGPulmonx Corporation
10/07/202422h05GlobeNewswire Inc.Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024NASDAQ:LUNGPulmonx Corporation
31/05/202422h38Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:LUNGPulmonx Corporation
06/05/202423h03GlobeNewswire Inc.Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LUNGPulmonx Corporation
01/05/202422h05GlobeNewswire Inc.Pulmonx Reports First Quarter 2024 Financial ResultsNASDAQ:LUNGPulmonx Corporation
10/04/202422h05GlobeNewswire Inc.Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024NASDAQ:LUNGPulmonx Corporation
02/04/202422h05GlobeNewswire Inc.Pulmonx Announces Appointment of Mehul Joshi as Chief Financial OfficerNASDAQ:LUNGPulmonx Corporation
08/03/202402h02Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LUNGPulmonx Corporation
29/02/202422h31Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LUNGPulmonx Corporation
27/02/202422h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LUNGPulmonx Corporation
27/02/202402h48Business WirePulmonx meldet Behandlung des ersten Patienten mit dem AeriSeal®-System in der CONVERT-II-ZulassungsstudieNASDAQ:LUNGPulmonx Corporation
27/02/202402h40Business WirePulmonx annonce le traitement du premier patient par système AeriSeal® dans l'essai pivot CONVERT IINASDAQ:LUNGPulmonx Corporation
27/02/202402h39Business WirePulmonx annuncia il trattamento del primo paziente con il sistema AeriSeal® nello studio pivotale CONVERT IINASDAQ:LUNGPulmonx Corporation
26/02/202414h00Business WirePulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal TrialNASDAQ:LUNGPulmonx Corporation
21/02/202422h06GlobeNewswire Inc.Pulmonx Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:LUNGPulmonx Corporation
 Showing the most relevant articles for your search:NASDAQ:LUNG